晶鑫國(guó)際鼎力支持樣本庫(kù)建設(shè) 贊助多場(chǎng)樣本庫(kù)會(huì)議
瀏覽次數(shù):3571 發(fā)布日期:2013-10-14
來源:本站 本站原創(chuàng),轉(zhuǎn)載請(qǐng)注明出處
九月,秋高氣爽的季節(jié),九月,碩果累累的季節(jié)。
九月,晶鑫國(guó)際贊助了《ISBER最佳實(shí)踐2012》&生物樣本庫(kù)崗前培訓(xùn),成功參加ABC2013 第三屆中國(guó)生物樣本庫(kù)國(guó)際研討會(huì),應(yīng)邀參加第二屆北京重大疾病臨床資源庫(kù)標(biāo)準(zhǔn)化建設(shè)國(guó)際會(huì)議。
This very busy September, GeneSyn sponsored various exciting industry Biobanking events such as the first official 《ISBER Best Practice 2012》training, Annual Biobank China 2013 as the third international conference, we were also invited to co-organize the second Beijing Biobank Standardization and Construction International Conference.
晶鑫國(guó)際作為生物樣本管理解決方案的專業(yè)服務(wù)商,借助這些會(huì)議,加強(qiáng)國(guó)內(nèi)國(guó)外相關(guān)從業(yè)人員之間的經(jīng)驗(yàn)交流,推動(dòng)國(guó)內(nèi)外機(jī)構(gòu)在樣本庫(kù)建設(shè)領(lǐng)域的合作,促進(jìn)生物樣本庫(kù)的建設(shè)和發(fā)展。生物樣本庫(kù)建設(shè)是各大醫(yī)學(xué)院、醫(yī)院尤其腫瘤醫(yī)院管理者的重大戰(zhàn)略舉措,目前已日趨成為獨(dú)立的單元,將可成為與藥庫(kù)、血庫(kù)等并駕齊驅(qū)的輔助科室,由具備專業(yè)技術(shù)的人員管理運(yùn)作,其中病理學(xué)專業(yè)人員比重日益增多。
As one of the most prestigious Biobank Total Solution Provider in China, GeneSyn has tremendously advanced industry communication and promoted collaboration with leading translational research organizations whereby boosted the quality construction and development of Chinese Biobanks. So far, biobanks has been introduced as the strategic and key development issue to many research facilities and research-driven hospitals, it has been more and more realized as a separate daily-basis operating unit and presumably will be as important as hospital drug house and blood bank, inevitably Biobanks will be managed by professionals who are specifically trained in translational research and biobank day-to-day operations, instead of current primarily running by pathologist.
晶鑫國(guó)際擁有一支非常專業(yè)的服務(wù)團(tuán)隊(duì),我們將以精湛技術(shù)和先進(jìn)產(chǎn)品服務(wù)于臨床轉(zhuǎn)化醫(yī)學(xué),推進(jìn)中國(guó)社會(huì)健康事業(yè)的發(fā)展。
GeneSyn has the most professional solution project advisors and service technicians, we will continue to provide the health industry with the most advanced technology and understandings in translational research.